Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]

Targeting agent enfortumab vedotin a novel treatment for patients with advanced...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

New agent targeting Nectin-4 produces responses in nearly half of patients with...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA...

Dr Hedy Kindler - University of Chicago, Chicago, USA

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations ( Dr Hedy Kindler - University of Chicago, Chicago, USA )

Enzalutamide improves survival for men with metastatic hormone-sensitive...

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer ( Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

Comment: Using enzalutamide will allow patients to avoid chemotherapy and...

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA

Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA )

Maintenance therapy with PARP inhibitor olaparib delays progression in patients...

Dr Hedy Kindler - University of Chicago, Chicago, USA

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer ( Dr Hedy Kindler - University of Chicago, Chicago, USA )

Comment: It is essential to identify the BRCA gene in pancreatic cancer...

Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent ( Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA )

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as...

Dr Edward B. Garon - UCLA, Los Angeles, USA

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal...

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona...

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )

Comment: Reasonable to conclude that pembrolizumab is non-inferior to...

Dr Richard Schilsky and Dr Josep Tabernero

Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy ( Dr Richard Schilsky and Dr Josep Tabernero )

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or...

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona...

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain )

More from ecancer